Viimased lisandused - Age-Related Macular Degeneration - Dry
|
Reticular pseudodrusenvaatamisi: 100veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 107veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 104veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 93veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 95veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 87veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 107veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 105veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 98veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 105veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 88veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 98veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 94veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 98veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 97veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 106veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 103veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 91veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 92veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 87veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 88veebr 23, 2025
|
|
54 year old female with a lot of drusenvaatamisi: 88VA 20/12 OD, 20/16 OS - no symptomsdets 21, 2024
|
|
54 year old female with a lot of drusenvaatamisi: 82VA 20/12 OD, 20/16 OS - no symptomsdets 21, 2024
|
|
54 year old female with a lot of drusenvaatamisi: 87VA 20/12 OD, 20/16 OS - no symptomsdets 21, 2024
|
|
54 year old female with a lot of drusenvaatamisi: 82VA 20/12 OD, 20/16 OS - no symptomsdets 21, 2024
|
|
54 year old female with a lot of drusenvaatamisi: 99VA 20/12 OD, 20/16 OS - no symptomsdets 21, 2024
|
|
54 year old female with a lot of drusenvaatamisi: 98VA 20/12 OD, 20/16 OS - no symptomsdets 21, 2024
|
|
54 year old female with a lot of drusenvaatamisi: 91VA 20/12 OD, 20/16 OS - no symptomsdets 21, 2024
|
|
54 year old female with a lot of drusenvaatamisi: 89VA 20/12 OD, 20/16 OS - no symptomsdets 21, 2024
|
|
Large Hyper-reflective drusen in age-related macular degenerationvaatamisi: 13669 year old healthy woman with 20/20 vision and no visual complaintssept 22, 2023
|
|
Large Hyper-reflective drusen in age-related macular degenerationvaatamisi: 14169 year old healthy woman with 20/20 vision and no visual complaintssept 22, 2023
|
|
Large Hyper-reflective drusen in age-related macular degenerationvaatamisi: 13169 year old healthy woman with 20/20 vision and no visual complaintssept 22, 2023
|
|
Large Hyper-reflective drusen in age-related macular degenerationvaatamisi: 12469 year old healthy woman with 20/20 vision and no visual complaintssept 22, 2023
|
|
Large Hyper-reflective drusen in age-related macular degenerationvaatamisi: 14369 year old healthy woman with 20/20 vision and no visual complaintssept 22, 2023
|
|
Large Hyper-reflective drusen in age-related macular degenerationvaatamisi: 14469 year old healthy woman with 20/20 vision and no visual complaintssept 22, 2023
|
|
Large Hyper-reflective drusen in age-related macular degenerationvaatamisi: 13369 year old healthy woman with 20/20 vision and no visual complaintssept 22, 2023
|
|
Large Hyper-reflective drusen in age-related macular degenerationvaatamisi: 12369 year old healthy woman with 20/20 vision and no visual complaintssept 22, 2023
|
|
Large Hyper-reflective drusen in age-related macular degenerationvaatamisi: 13569 year old healthy woman with 20/20 vision and no visual complaintssept 22, 2023
|
|
Dry Macular Degeneration with Pseudodrusen and vitelliform lesionvaatamisi: 12180 year old female with 20/50 vision in both eyes. Mild blurringsept 17, 2023
|
|
Dry Macular Degeneration with Pseudodrusen and vitelliform lesionvaatamisi: 11280 year old female with 20/50 vision in both eyes. Mild blurringsept 17, 2023
|
|
Dry Macular Degeneration with Pseudodrusen and vitelliform lesionvaatamisi: 10480 year old female with 20/50 vision in both eyes. Mild blurringsept 17, 2023
|
|
Dry Macular Degeneration with Pseudodrusen and vitelliform lesionvaatamisi: 10280 year old female with 20/50 vision in both eyes. Mild blurringsept 17, 2023
|
|
Dry Macular Degeneration with Pseudodrusen and vitelliform lesionvaatamisi: 10980 year old female with 20/50 vision in both eyes. Mild blurringsept 17, 2023
|
|
Dry Macular Degeneration with Pseudodrusen and vitelliform lesionvaatamisi: 13080 year old female with 20/50 vision in both eyes. Mild blurringsept 17, 2023
|
|
Dry Macular Degeneration with Pseudodrusen and vitelliform lesionvaatamisi: 12880 year old female with 20/50 vision in both eyes. Mild blurringsept 17, 2023
|
|
Dry Macular Degeneration with Pseudodrusen and vitelliform lesionvaatamisi: 11180 year old female with 20/50 vision in both eyes. Mild blurringsept 17, 2023
|
|
Dry Macular Degeneration with Pseudodrusen and vitelliform lesionvaatamisi: 13080 year old female with 20/50 vision in both eyes. Mild blurringsept 17, 2023
|
|
Optic Disc Melanocytoma - Atypicalvaatamisi: 24745 year old female with normal vision and optic nerve lesion in the left eye. VA 20/16 OU. Extensive testing was normal including brain and orbit MRI. The lesion has been stable for 5 years.aug 17, 2022
|
|
Optic Disc Melanocytoma - Atypicalvaatamisi: 22145 year old female with normal vision and optic nerve lesion in the left eye. VA 20/16 OU. Extensive testing was normal including brain and orbit MRI. The lesion has been stable for 5 years.aug 17, 2022
|
|
Optic Disc Melanocytoma - Atypicalvaatamisi: 21945 year old female with normal vision and optic nerve lesion in the left eye. VA 20/16 OU. Extensive testing was normal including brain and orbit MRI. The lesion has been stable for 5 years.aug 17, 2022
|
|
Optic Disc Melanocytoma - Atypicalvaatamisi: 22145 year old female with normal vision and optic nerve lesion in the left eye. VA 20/16 OU. Extensive testing was normal including brain and orbit MRI. The lesion has been stable for 5 years.aug 17, 2022
|
|
Optic Disc Melanocytoma - Atypicalvaatamisi: 21645 year old female with normal vision and optic nerve lesion in the left eye. VA 20/16 OU. Extensive testing was normal including brain and orbit MRI. The lesion has been stable for 5 years.aug 17, 2022
|
|
Optic Disc Melanocytoma - Atypicalvaatamisi: 22445 year old female with normal vision and optic nerve lesion in the left eye. VA 20/16 OU. Extensive testing was normal including brain and orbit MRI. The lesion has been stable for 5 years.aug 17, 2022
|
|
Optic Disc Melanocytoma - Atypicalvaatamisi: 22245 year old female with normal vision and optic nerve lesion in the left eye. VA 20/16 OU. Extensive testing was normal including brain and orbit MRI. The lesion has been stable for 5 years.aug 17, 2022
|
|
Optic Disc Melanocytoma - Atypicalvaatamisi: 22445 year old female with normal vision and optic nerve lesion in the left eye. VA 20/16 OU. Extensive testing was normal including brain and orbit MRI. The lesion has been stable for 5 years.aug 17, 2022
|
|
Optic Disc Melanocytoma - Atypicalvaatamisi: 23645 year old female with normal vision and optic nerve lesion in the left eye. VA 20/16 OU. Extensive testing was normal including brain and orbit MRI. The lesion has been stable for 5 years.aug 17, 2022
|
|
Optic Disc Melanocytoma - Atypicalvaatamisi: 22945 year old female with normal vision and optic nerve lesion in the left eye. VA 20/16 OU. Extensive testing was normal including brain and orbit MRI. The lesion has been stable for 5 years.aug 17, 2022
|
|
Optic Disc Melanocytoma - Atypicalvaatamisi: 25345 year old female with normal vision and optic nerve lesion in the left eye. VA 20/16 OU. Extensive testing was normal including brain and orbit MRI. The lesion has been stable for 5 years.aug 17, 2022
|
|
Dry AMD - Pigment - AREDS risk score of 4vaatamisi: 23465 year old woman with 20/32 vision. A little blurred. Pigment and large drusen in each eye. AREDS risk score of four.aug 17, 2022
|
|
Dry AMD - Pigment - AREDS risk score of 4vaatamisi: 22165 year old woman with 20/32 vision. A little blurred. Pigment and large drusen in each eye. AREDS risk score of four.aug 17, 2022
|
|
Dry AMD - Pigment - AREDS risk score of 4vaatamisi: 22165 year old woman with 20/32 vision. A little blurred. Pigment and large drusen in each eye. AREDS risk score of four.aug 17, 2022
|
|
Dry AMD - Pigment - AREDS risk score of 4vaatamisi: 23065 year old woman with 20/32 vision. A little blurred. Pigment and large drusen in each eye. AREDS risk score of four.aug 17, 2022
|
|
Dry AMD - Pigment - AREDS risk score of 4vaatamisi: 21965 year old woman with 20/32 vision. A little blurred. Pigment and large drusen in each eye. AREDS risk score of four.aug 17, 2022
|
|
Dry AMD - Pigment - AREDS risk score of 4vaatamisi: 21965 year old woman with 20/32 vision. A little blurred. Pigment and large drusen in each eye. AREDS risk score of four.aug 17, 2022
|
|
Dry AMD - Pigment - AREDS risk score of 4vaatamisi: 20665 year old woman with 20/32 vision. A little blurred. Pigment and large drusen in each eye. AREDS risk score of four.aug 17, 2022
|
|
Dry AMD - Pigment - AREDS risk score of 4vaatamisi: 23365 year old woman with 20/32 vision. A little blurred. Pigment and large drusen in each eye. AREDS risk score of four.aug 17, 2022
|
|
Dry AMD - Pigment - AREDS risk score of 4vaatamisi: 20565 year old woman with 20/32 vision. A little blurred. Pigment and large drusen in each eye. AREDS risk score of four.aug 17, 2022
|
|
Dry AMD - Pigment - AREDS risk score of 4vaatamisi: 19365 year old woman with 20/32 vision. A little blurred. Pigment and large drusen in each eye. AREDS risk score of four.aug 17, 2022
|
|
Soft Drusenvaatamisi: 24563 year old female with 20/16 vision both eyesokt 17, 2021
|
|
Soft Drusenvaatamisi: 26263 year old female with 20/16 vision both eyesokt 17, 2021
|
|
Soft Drusenvaatamisi: 24463 year old female with 20/16 vision both eyesokt 17, 2021
|
|
Soft Drusenvaatamisi: 23563 year old female with 20/16 vision both eyesokt 17, 2021
|
|
Soft Drusenvaatamisi: 24163 year old female with 20/16 vision both eyesokt 17, 2021
|
|
Soft Drusenvaatamisi: 27763 year old female with 20/16 vision both eyesokt 17, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 25779 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 23379 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 24379 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 24979 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 25179 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 24779 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 27279 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 25479 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 25079 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 28479 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 26979 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 23579 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 25879 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 24479 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 22379 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 25279 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 24379 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 26679 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 26679 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 26779 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 22079 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 23879 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 26479 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 25979 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 25879 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 28279 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
|
|
